With yearslong reorganization behind it, Novartis increases its sales guidancenews2024-11-21T21:27:52+00:00November 21st, 2024|Endpoints News|
FDA adcomm raises risk questions on AstraZeneca’s Andexxanews2024-11-21T21:14:50+00:00November 21st, 2024|Endpoints News|
AstraZeneca culls Phase 2 opioid use disorder drugnews2024-11-21T20:54:54+00:00November 21st, 2024|Endpoints News|
Jazz wins approval for bispecific in biliary tract cancernews2024-11-21T19:17:39+00:00November 21st, 2024|Endpoints News|
At Jefferies, all that manufacturers want to talk about is GLP-1snews2024-11-21T17:27:01+00:00November 21st, 2024|Endpoints News|
Trump and RFK Jr. want to ban pharma ads. History isn’t on their sidenews2024-11-21T16:59:15+00:00November 21st, 2024|Endpoints News|
Samsung Bio’s new $668M client; Sanofi expands a factory in Francenews2024-11-21T16:48:43+00:00November 21st, 2024|Endpoints News|
Cidara’s $100M PIPE; Pyxis Oncology’s stock falls on Phase 1 datanews2024-11-21T15:49:18+00:00November 21st, 2024|Endpoints News|
FDA vaccine chief Peter Marks pledges to stay as long as he’s welcomenews2024-11-21T15:46:12+00:00November 21st, 2024|Endpoints News|
Aizen debuts with AI-driven ‘mirror peptide’ platformnews2024-11-21T11:26:10+00:00November 21st, 2024|Endpoints News|
